Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti MA, Venditti A, Santini V; Ad Hoc Italian Cooperative Study Group on Azacitidine in Myelodysplastic Syndromes Acute Leukemias. Musto P, et al. Among authors: maurillo l. Cancer. 2010 Mar 15;116(6):1485-94. doi: 10.1002/cncr.24894. Cancer. 2010. PMID: 20151429 Free article.
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis.
Falconi G, Galossi E, Fabiani E, Pieraccioli M, Travaglini S, Hajrullaj H, Cerretti R, Palmieri R, Latagliata R, Maurillo L, Voso MT. Falconi G, et al. Among authors: maurillo l. Sci Rep. 2022 Dec 8;12(1):21231. doi: 10.1038/s41598-022-24644-1. Sci Rep. 2022. PMID: 36481766 Free PMC article.
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Lo-Coco F, Amadori S. Venditti A, et al. Among authors: maurillo l. Leukemia. 2003 Nov;17(11):2178-82. doi: 10.1038/sj.leu.2403138. Leukemia. 2003. PMID: 14576731 Clinical Trial.
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
Del Poeta G, Del Principe MI, Consalvo MA, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianní L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S. Del Poeta G, et al. Among authors: maurillo l. Cancer. 2005 Dec 15;104(12):2743-52. doi: 10.1002/cncr.21535. Cancer. 2005. PMID: 16284990 Free article. Clinical Trial.
Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.
Del Poeta G, Ilaria Del Principe M, Buccisano F, Maurillo L, Niscola P, Venditti A, Amadori S. Del Poeta G, et al. Among authors: maurillo l. Expert Rev Anticancer Ther. 2006 Dec;6(12):1787-800. doi: 10.1586/14737140.6.12.1787. Expert Rev Anticancer Ther. 2006. PMID: 17181492 Review.
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, Del Principe MI, Mazzone C, Consalvo MI, Tamburini A, Ottaviani L, Fraboni D, Sarlo C, De Fabritiis P, Amadori S, Venditti A. Maurillo L, et al. Haematologica. 2007 May;92(5):605-11. doi: 10.3324/haematol.10432. Haematologica. 2007. PMID: 17488683 Free article.
139 results